To further characterize the systemic and local microenvironmental immune landscape of rLAS-uPA-treated tumors, comparative transcriptomic analyses in pre- and post-treatment tumor samples and expanded multiplex cytokine assays should be considered in future study designs. The gene discussed is PLAU; the disease is neoplasm.